More Weight Loss Linked With More Benefit in STEP-HFpEF

Prespecified analysis of the STEP-HFpEF trial of semaglutide in people with obesity and heart failure with preserved ejection fraction showed a positive link between weight-loss amounts and outcomes.
Medscape Medical News

source https://www.medscape.com/viewarticle/995903?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?